Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.10
+0.05 (0.18%)
Nov 13, 2026, 1:30 PM CST

Tanvex BioPharma Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
602.71878.71376.96380.75786.232,223
Cash & Short-Term Investments
602.71878.71376.96380.75786.232,223
Cash Growth
-56.73%133.11%-1.00%-51.57%-64.63%7.46%
Accounts Receivable
131.2867.320.079.40.332.52
Other Receivables
88.5489.331.5827.4327.3625.31
Receivables
219.82156.6231.6536.8327.6927.84
Inventory
297.71420.71217.84108.29170.8490.33
Prepaid Expenses
82.5140.0949.1878.3558.9560.85
Other Current Assets
0.051.06----
Total Current Assets
1,2031,497675.62604.211,0442,402
Property, Plant & Equipment
2,6592,7611,8271,9282,1512,114
Goodwill
-2,910----
Other Intangible Assets
3,395485.327.073.3812.0710.17
Long-Term Deferred Tax Assets
12.186.34----
Other Long-Term Assets
34.71301.22225.3227.67213.47187.58
Total Assets
7,5137,9612,7352,7633,4204,714

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
11.18102.99----
Accrued Expenses
-147.64134.27-115.93137.49
Short-Term Debt
453.530----
Current Portion of Leases
195.46181.63160.01163.45124.6588.75
Current Income Taxes Payable
26.8926.89----
Current Unearned Revenue
162.9179.311.116.9128.07-
Other Current Liabilities
311.43231.2142.75193.3834.6322.28
Total Current Liabilities
1,161799.66348.14363.73303.29248.51
Long-Term Debt
433.01-----
Long-Term Leases
1,2471,3671,4881,5681,7151,670
Long-Term Unearned Revenue
96.35995.4710.23--
Other Long-Term Liabilities
1.721.72--10.47-
Total Liabilities
2,9402,2671,8421,9422,0281,919

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
2,6522,6491,6411,3403,5273,525
Additional Paid-In Capital
18,91218,90613,56712,43111,06110,988
Retained Earnings
-16,808-15,637-14,136-12,755-12,969-11,327
Comprehensive Income & Other
-183.22-223.63-177.94-194.17-227.09-390.12
Shareholders' Equity
4,5735,694893.31821.111,3912,795
Total Liabilities & Equity
7,5137,9612,7352,7633,4204,714

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,3291,5781,6481,7321,8391,759
Net Cash (Debt)
-1,727-699.69-1,271-1,351-1,053463.95
Net Cash Growth
------15.52%
Net Cash Per Share
-6.52-2.86-8.19-10.48-8.954.27
Filing Date Shares Outstanding
264.99264.86164.07133.96117.64117.57
Total Common Shares Outstanding
264.99264.86164.07133.96117.64117.57
Working Capital
41.43697.52327.48240.48740.432,153
Book Value Per Share
17.2621.505.446.1311.8323.77
Tangible Book Value
1,1782,298886.24817.731,3792,785
Tangible Book Value Per Share
4.458.685.406.1011.7323.68
Machinery
-1,1261,089982.54975.18889.53
Construction In Progress
-849.5544.3483.7172.8253.8
Leasehold Improvements
-517.23509.94415.69388.62318.95